Clinical Trials Logo

Clinical Trial Summary

Our aim in this cross-sectional study is to determine the frequency and aspects of gallbladder dysfunction and the related risk factors in pre-ESRD and hemodialysis patients.


Clinical Trial Description

Biliary tract disorders including cholelithiasis, cholecystitis, and other diseases of the biliary tract, are one of the most prevalent medical issues in the digestive system, posing a myriad of challenges for health workers and patients. Gallbladder dysfunction is the most frequent cause of symptomatic and complicated biliary tract disorders. Although gallbladder dysfunction is a common condition in Middle East countries, data on the incidence of end-stage renal disease (ESRD) are limited. The occurrence of gallbladder dysfunction in patients fed with low-protein diets suggests that gallbladder stones formation is affected by dietary protein content. Also the lithogenic composition changes of bile, increased nucleation tendency, and impaired motility of gallbladder are important factors in ESRD patients. It has been reported that chronic kidney disease (CKD) patients on regular hemodialysis (HD) have increased bile cholesterol levels and an increased bile saturation index. In addition, the gallbladder is innervated by the autonomic nervous system, which malfunctions in uremia, and it has been shown that gallbladder stasis might cause increased stone formation. In some studies, the prevalence of gallbladder dysfunction has been shown to increase in patients undergoing hemodialysis (HD) treatment for ESRD. So, we focused in this study to try to find association of gallbladder dysfunction in pre-dialysis ESRD and HD patient in comparison to normal renal function individuals. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06437418
Study type Observational
Source Assiut University
Contact Rehab Mohamed Mohamed Eltayeb, M.B.B.CH.
Phone 01016644593
Email rehab.eltaib@med.aun.edu.eg
Status Not yet recruiting
Phase
Start date June 2024
Completion date July 2025

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03277911 - Thyroid Dysfunction and Dyslipidemia in Patients With Chronic Kidney Diseases N/A
Active, not recruiting NCT04008810 - Serum Neutrophil Gelatinase-associated Lipocalins (NGAL) and Chronic Kidney Disease
Completed NCT05144971 - StatStrip A Glucose/Creatinine Meter System Lay User Study Evaluation
Active, not recruiting NCT05356325 - FGF23 and Cardiovascular Damage in Anemia With an Without Chronic Kidney Disease.
Not yet recruiting NCT04491669 - Screening of Gastrointestinal Tract Bleeding Causes Among Chronic Renal Failure Patients
Completed NCT04709120 - Analysis of Health Status of Сomorbid Adult COVID-19 Patients Hospitalised in Second Wave of SARS-CoV-2 Infection
Terminated NCT03277183 - Frequent, Low-Dose Erythropoietin A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin Phase 4
Enrolling by invitation NCT04491227 - Global Assessment of Acute and Chronic Kidney Disease Incidence and Outcomes in Patients With COVID-19 Infection
Recruiting NCT06279429 - Sucrosomial Iron on Insomnia in Non-dialysis Chronic Kidney Disease Patients With Iron Deficiency Anemia N/A
Recruiting NCT03501745 - Smart-CKD/BP Study N/A
Recruiting NCT04708743 - The Tongue Features Associated With Chronic Kidney Disease
Recruiting NCT06416761 - Genetics in the Progression of Nephropathies
Completed NCT04119570 - CKD Report Card Pilot Trial N/A
Completed NCT06374043 - Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin. Phase 4
Not yet recruiting NCT06094920 - Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial Phase 4
Recruiting NCT04819217 - Study of Oral Uremic Toxin Absorbent and Probiotics to Retard the Progression of Chronic Kidney Disease N/A
Completed NCT05970094 - Reduction of Metabolic Acidosis in Patients With Chronic Kidney Disease in Stage 4 and 5 N/A
Withdrawn NCT04782297 - Long Term Hemodialysis Catheters (LTHD) Post Market Clinical Follow up (PMCF)
Recruiting NCT05784389 - Reduction of Metabolic Acidosis in Patients With Chronic Kidney Disease in Stage 4 and 5 N/A
Recruiting NCT04630132 - Renal Ageing-sarcopenia Network